Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patient has symptoms of Stress Urinary Incontinence (SUI) for at least 12 weeks prior to study entry~* Urinary incontinence in the 1-hour pad weight test exceeds 2.0 g~* The average number of SUI episodes is 1 or more per day~* The average number of urge urinary incontinence (UUI) episodes is 0.43 or less per day~* The number of SUI episodes exceeds the number of other episodes~* The average number of urinary diurnal frequency is 10 or less per day and the average number of nocturia frequency is 2 or less per day~Key Exclusion Criteria:~* Patient has been diagnosed with mixed urinary incontinence (MUI) that is predominantly UUI~* Patient has treated medication or therapy for SUI within 14 days before prior to study entry~* Patient is considered to have SUI that would not be expected to improve unless treated with surgical therapy~* Patient had a history of surgical treatment for urinary incontinence (Trans-obturator tape surgery, Tension-free vaginal tape surgery, etc.)~* Patient has stage II or more of Pelvic Organ Prolapse (POP), or had a history of POP repair surgery within 180 days before prior to study entry~* Patient has a serious illness or medical condition

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS-303 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).